Biohaven Pharmaceuticals, Inc: Lead program is rimegepant, oral CGRP antagonist (targeting migraine); recently (2Q 2019) submitted NDAs for Zydis ODT (orally dissolving tablet) and tablet formulations of rimegepant. Presented expanded data at AHS (July 2019) /dosed 1,780+ patients (combined exposure of 105k doses) and expanded safety & prelim preventive efficacy data (May 2019) from long-term safety study. Upcoming milestones: Ph 3 topline data in preventive treatment of migraine (rimegepant) & Ph 2/3 topline efficacy & safety in intranasal (BHV-3500) for acute treatment of migraine in 4Q19. Advancing ODT & tablet formulations toward commercialization. Continuing to enroll pts in Ph 2 POC in trigeminal neuralgia. Glutamate platform (focusing on troriluzole) studies ongoing in AD, OCD, GAD, and SCA.
Based in...
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Public, USA
Market Cap
500MM +
Therapeutic Modalities
Small Molecule
215 Church Street
New Haven, CT 06510
United States

Company Participants at Biohaven Investor and Clinician Dinner in Philadelphia

  • Vlad Coric, M.D., Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.